热景生物：关于参股公司SGC001创新药Ib期临床研究获得积极初步结果的自愿披露公告

Core Insights - The company, 热景生物, announced that its affiliate, 北京舜景生物医药技术有限公司, reported positive preliminary results from the Phase Ib clinical trial of its innovative drug SGC001 injection [2] Group 1 - The innovative drug SGC001 is being developed by 北京舜景生物医药技术有限公司, which is a subsidiary of 热景生物 [2] - The Phase Ib clinical trial has yielded encouraging initial results, indicating potential for further development [2]